newsfilter
← Latest News
GlobeNewswire·

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

VERA
  • William Turner is retiring as Chief Regulatory Officer at Vera Therapeutics in Q3 2026 to become a Strategic Advisor.
  • Dr. Nancy Boman succeeds Turner as the new Chief Regulatory Officer effective immediately.
  • Turner's tenure included leading the regulatory strategy for the accelerated approval of the company's first therapy, TRUTAKNA (atacicept-vymj), for IgA nephropathy.
  • Boman brings over 25 years of regulatory experience, having previously served as Chief Regulatory Officer at Kyverna Therapeutics, Adicet Bio, Encoded Therapeutics, & Novartis Gene Therapies.
  • Boman holds an M.D. & Ph.D. in biochemistry from the University of British Columbia & began her career as a scientist at companies including Amgen, Genentech, & Alder.
  • CEO Marshall Fordyce stated Boman's medical & scientific background will support future work on new indications for TRUTAKNA in autoimmune kidney diseases.
  • TRUTAKNA is indicated to reduce proteinuria in adults with primary IgAN at risk for disease progression under accelerated approval based on proteinuria reduction.
  • Important safety information notes TRUTAKNA is contraindicated in patients with serious hypersensitivity to the drug.
  • Warnings indicate increased risk of infections due to immunosuppression, with 32% of patients reporting infections in clinical trials.
  • Live vaccines are not recommended within 30 days prior to initiation or during treatment due to potential interference with immune response.
  • The drug's safety & effectiveness in pediatric patients have not been established, & insufficient data exists regarding use in pregnant women.